home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 11/11/22

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - Immix Biopharma gets review board nod to enroll kids in upcoming cancer therapy trial

Immix Biopharma ( NASDAQ: IMMX ) on Friday said it had got an approval from an institutional review board to enroll children in its upcoming clinical trial of its IMX-110 therapy for the treatment of rhabdomyosarcoma. Rhabdomyosarcoma is a rare type of cancer that forms i...
IMMX - Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a...

IMMX - Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, &#x...

IMMX - ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

California Soft Tissue Sarcoma Site to lead expanded clinical site consortium Historically, high-enrolling lead site has enrolled 2-3 patients per month Clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT sca...
IMMX - ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tum...

IMMX - Bluejay, DBV top healthcare gainers; Precision, Blueprint among losers' pack

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

IMMX - Immix, Bright Green top healthcare gainers; while Zosano, Immunic lead losers' pack

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...
IMMX - IMMX, ZY and SCOR among premarket gainers

Immix Biopharma (IMMX) +37%. Repare Therapeutics RPTX +28% on signing licensing deal with Repare Therapeutics for tumor candidate. Chewy CHWY +20% on Q1 results. UiPath PATH +12% on Q1 results. Blue Apron Holdings APRN +11% after launch of meal kits on ...

IMMX - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CASI Pharmaceuticals (NASDAQ: CASI ) stock tops out pre-market gainers. Immunic (NASDAQ: IMUX ) stock leads our pre-market losers. Several stocks are pulling back after rallies yesterday. Source: f11ph...

IMMX - SAVA, BKSY and SEMR among mid-day movers

Gainers: TherapeuticsMD (TXMD) +361%. JanOne (JAN) +70%. Houston American Energy (HUSA) +57%. CatchMark Timber Trust (CTT) +44%. Mullen Automotive (MULN) +43%. Gogoro (GGR) +37%. BlackSky Technology (BKSY) +32%. Cassava Sciences (SAVA) +25%. MicroStrategy (MSTR) +24%. NexImmune (NEXI) +23%. L...
Previous 10 Next 10